These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 30878184)

  • 1. Structure-based identification of novel CK2 inhibitors with a linear 2-propenone scaffold as anti-cancer agents.
    Qi X; Zhang N; Zhao L; Hu L; Cortopassi WA; Jacobson MP; Li X; Zhong R
    Biochem Biophys Res Commun; 2019 Apr; 512(2):208-212. PubMed ID: 30878184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based Discovery of Novel CK2α-Binding Cyclic Peptides with Anti-cancer Activity.
    Tang S; Zhang N; Zhou Y; Cortopassi WA; Jacobson MP; Zhao LJ; Zhong RG
    Mol Inform; 2019 Mar; 38(3):e1800089. PubMed ID: 30307134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rational Design of Coumarin Derivatives as CK2 Inhibitors by Improving the Interaction with the Hinge Region.
    Zhang N; Chen WJ; Zhou Y; Zhao H; Zhong RG
    Mol Inform; 2016 Jan; 35(1):15-8. PubMed ID: 27491649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of 5-(3-Chlorophenylamino)benzo[
    Wang Y; Lv Z; Chen F; Wang X; Gou S
    J Med Chem; 2021 Apr; 64(8):5082-5098. PubMed ID: 33834781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ethyl 2-(benzylidene)-7-methyl-3-oxo-2,3-dihydro-5H-thiazolo[3,2-a]pyrimidine-6-carboxylate analogues as a new scaffold for protein kinase casein kinase 2 inhibitor.
    Jin CH; Jun KY; Lee E; Kim S; Kwon Y; Kim K; Na Y
    Bioorg Med Chem; 2014 Sep; 22(17):4553-65. PubMed ID: 25131958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the Pivotal Role of the CK2 Hinge Region Sub-Pocket in Binding with Tricyclic Quinolone Analogues by Computational Analysis.
    Zhou Y; Zhang N; Tang S; Qi X; Zhao L; Zhong R; Peng Y
    Molecules; 2017 May; 22(5):. PubMed ID: 28534839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based design of novel potent protein kinase CK2 (CK2) inhibitors with phenyl-azole scaffolds.
    Hou Z; Nakanishi I; Kinoshita T; Takei Y; Yasue M; Misu R; Suzuki Y; Nakamura S; Kure T; Ohno H; Murata K; Kitaura K; Hirasawa A; Tsujimoto G; Oishi S; Fujii N
    J Med Chem; 2012 Mar; 55(6):2899-903. PubMed ID: 22339433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of novel substituted pyrrolo[1,2-a]quinoxaline derivatives as inhibitors of the human protein kinase CK2.
    Guillon J; Le Borgne M; Rimbault C; Moreau S; Savrimoutou S; Pinaud N; Baratin S; Marchivie M; Roche S; Bollacke A; Pecci A; Alvarez L; Desplat V; Jose J
    Eur J Med Chem; 2013 Jul; 65():205-22. PubMed ID: 23711832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent Advances in the Discovery of CK2 Allosteric Inhibitors: From Traditional Screening to Structure-Based Design.
    Chen X; Li C; Wang D; Chen Y; Zhang N
    Molecules; 2020 Feb; 25(4):. PubMed ID: 32079098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and Biological Evaluation of CK2 Allosteric Fragments through Structure-Based Virtual Screening.
    Li C; Zhang X; Zhang N; Zhou Y; Sun G; Zhao L; Zhong R
    Molecules; 2020 Jan; 25(1):. PubMed ID: 31935979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity relationship study of 4-(thiazol-5-yl)benzoic acid derivatives as potent protein kinase CK2 inhibitors.
    Ohno H; Minamiguchi D; Nakamura S; Shu K; Okazaki S; Honda M; Misu R; Moriwaki H; Nakanishi S; Oishi S; Kinoshita T; Nakanishi I; Fujii N
    Bioorg Med Chem; 2016 Mar; 24(5):1136-41. PubMed ID: 26850376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Casein Kinase II (CK2) as a Therapeutic Target for Hematological Malignancies.
    Gowda C; Sachdev M; Muthusami S; Kapadia M; Petrovic-Dovat L; Hartman M; Ding Y; Song C; Payne JL; Tan BH; Dovat S
    Curr Pharm Des; 2017; 23(1):95-107. PubMed ID: 27719640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological properties and structural study of new aminoalkyl derivatives of benzimidazole and benzotriazole, dual inhibitors of CK2 and PIM1 kinases.
    Chojnacki K; Wińska P; Wielechowska M; Łukowska-Chojnacka E; Tölzer C; Niefind K; Bretner M
    Bioorg Chem; 2018 Oct; 80():266-275. PubMed ID: 29966873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and biological evaluation of new embelin derivatives as CK2 inhibitors.
    Oramas-Royo S; Haidar S; Amesty Á; Martín-Acosta P; Feresin G; Tapia A; Aichele D; Jose J; Estévez-Braun A
    Bioorg Chem; 2020 Jan; 95():103520. PubMed ID: 31887475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel class of selective CK2 inhibitors targeting its open hinge conformation.
    Dalle Vedove A; Zonta F; Zanforlin E; Demitri N; Ribaudo G; Cazzanelli G; Ongaro A; Sarno S; Zagotto G; Battistutta R; Ruzzene M; Lolli G
    Eur J Med Chem; 2020 Jun; 195():112267. PubMed ID: 32283296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and synthesis of novel protein kinase CK2 inhibitors on the base of 4-aminothieno[2,3-d]pyrimidines.
    Ostrynska OV; Balanda AO; Bdzhola VG; Golub AG; Kotey IM; Kukharenko OP; Gryshchenko AA; Briukhovetska NV; Yarmoluk SM
    Eur J Med Chem; 2016 Jun; 115():148-60. PubMed ID: 27017545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and design of tricyclic scaffolds as protein kinase CK2 (CK2) inhibitors through a combination of shape-based virtual screening and structure-based molecular modification.
    Sun H; Xu X; Wu X; Zhang X; Liu F; Jia J; Guo X; Huang J; Jiang Z; Feng T; Chu H; Zhou Y; Zhang S; Liu Z; You Q
    J Chem Inf Model; 2013 Aug; 53(8):2093-102. PubMed ID: 23937544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An overview about the impact of hinge region towards the anticancer binding affinity of the Ck2 ligands: a quantum chemical analysis.
    Deepa P; Thirumeignanam D; Kolandaivel P
    J Biomol Struct Dyn; 2019 Sep; 37(15):3859-3876. PubMed ID: 30301411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
    Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based design and synthesis of novel macrocyclic pyrazolo[1,5-a] [1,3,5]triazine compounds as potent inhibitors of protein kinase CK2 and their anticancer activities.
    Nie Z; Perretta C; Erickson P; Margosiak S; Lu J; Averill A; Almassy R; Chu S
    Bioorg Med Chem Lett; 2008 Jan; 18(2):619-23. PubMed ID: 18055206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.